Drugs.com - New Drug Approvals

FDA Approves an Updated Label for Tryvio (aprocitentan) Removing the REMS Requirement

Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on...

Apr 16, 2025 - 06:00
 0
FDA Approves an Updated Label for Tryvio (aprocitentan) Removing the REMS Requirement
Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on...
Read More

Tags:

Previous Article

Bangladesh's RMG exports up 10.8% to $30.2 bn in July-March FY25

Next Article

Fortescue breaks ground on 190MW solar PV plant in Western Australia, eyes ‘real...

Related Posts

Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer

Imfinzi Approved in the US as First and Only Immunother...

Feb 9, 2025  0

Theratechnologies Receives FDA Approval for Egrifta WR (tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies Receives FDA Approval for Egrifta WR ...

Mar 29, 2025  0

Tevimbra Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

Tevimbra Approved in U.S. for First-line Treatment of G...

Feb 9, 2025  0